Whitepapers

Sep 07, 2017
Sponsored Content
As drug developers face increasing pressure to get their products to market as quickly as possible, read an economist’s viewpoint of how single-source networks cut development timelines.
Sep 07, 2017
Sponsored Content
A single-source CDMO that manages the end-to-end relationship with pharmaceutical clients can bring many efficiencies to the development process. Learn why smaller companies, in particular, may benefit from working with a large, single-source vendor.
Aug 16, 2017
Sponsored Content
Samples are valuable research assets. The integration of sample inventory data with phenotypical, clinical, laboratory, and consent data is a challenge for biobanks, biorepositories, and research organizations. BioStudies enables the complete optimization of the value associated with your sample assets by connecting this information together in a single solution.
Aug 15, 2017
Sponsored Content
By EtQ
Download this white paper to learn how a risk-focused QMS streamlines compliance by creating an entire system around a central focus.
Aug 11, 2017
Sponsored Content
The ultimate goal of formulation development is a stable product. A well-designed product development plan can develop a Phase I product quickly, while laying the foundation for commercial product success.
Aug 10, 2017
Sponsored Content
A single vendor offers access to a network of experts across several disciplines who can share knowledge about a project as it moves from phase to phase, thus helping to navigate its path toward commercial success. Following a CPhI North America panel about single-source CDMOs, Pharmaceutical Technology spoke with Paul Nelson, vice president of supply chain and R&D at Amring Pharmaceuticals, about his experience with single-source CDMOs.
Aug 10, 2017
Sponsored Content
In the pharma industry, speed is of the essence. The Patheon OneSourceTM model exemplifies the benefits of an end-to-end supply chain for pharma and biopharma clients by accelerating time to clinic and to market, adding cost savings, and putting formulations on the path to regulatory success. Following a CPhI North America panel on single-vendor CDMOs, PharmTech spoke with Anil Kane, PhD, executive director and global head of technical and scientific affairs at Patheon, to talk about his views on the subject.
Jul 22, 2017
Sponsored Content
Nutritional ketosis increases brain ketone uptake and can be safely achieved by medium-chain triglyceride supplements. Several clinical studies have assessed whether MCT can restore brain energy supply and reduce memory impairment in Alzheimer’s disease, some with more success than others.
Jul 19, 2017
Sponsored Content
The CDMO industry has been evolving to meet the need for increased efficiency during drug development, spurring some larger providers to offer forward-thinking end-to-end supply chain solutions for pharmaceutical and biopharmaceutical clients. In “Single-Vendor CDMOs Bring Speed and Cost Savings to the Table,” hear from a panel of industry experts about how working with a single-source CDMO partner can accelerate time to market, add cost savings, and improve a formulation’s chances of achieving regulatory success.
Jul 13, 2017
Sponsored Content
What new strategies are available to help drug developers bring patient-friendly products to market quickly and cost effectively? In a new PharmTech ebook on A Data-Driven Approach to Overcome Bioavailability Challenges, experts explain how the structured and parallel screening of solubility-enhancing techniques helps accomplish this goal while also solving complex bioavailability and formulation challenges for early-stage compounds. In addition, this eBook offers an in-depth look at how lipid-based drug delivery systems can be used as a bioavailability-enhancing technology.
native1_300x100
lorem ipsum